 Debashis Ghosh
Concepts (712)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 52 | 2023 | 1510 | 4.700 |
Why?
| | Data Interpretation, Statistical | 27 | 2020 | 315 | 4.690 |
Why?
| | Models, Statistical | 42 | 2021 | 593 | 4.190 |
Why?
| | Algorithms | 37 | 2023 | 1462 | 3.840 |
Why?
| | Oligonucleotide Array Sequence Analysis | 35 | 2016 | 739 | 3.190 |
Why?
| | Biomarkers, Tumor | 24 | 2022 | 1029 | 2.480 |
Why?
| | Metabolomics | 9 | 2022 | 508 | 2.430 |
Why?
| | Computer Simulation | 33 | 2023 | 858 | 2.360 |
Why?
| | Machine Learning | 8 | 2022 | 316 | 2.310 |
Why?
| | Biometry | 13 | 2011 | 62 | 2.220 |
Why?
| | Neoplasms | 24 | 2022 | 2082 | 1.920 |
Why?
| | Regression Analysis | 13 | 2021 | 932 | 1.540 |
Why?
| | Genomics | 12 | 2024 | 625 | 1.500 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 902 | 1.440 |
Why?
| | Computational Biology | 17 | 2021 | 527 | 1.420 |
Why?
| | Prostatic Neoplasms | 25 | 2012 | 911 | 1.420 |
Why?
| | Models, Biological | 14 | 2021 | 1589 | 1.410 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 381 | 1.400 |
Why?
| | Biomarkers | 14 | 2021 | 3389 | 1.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 22 | 2021 | 1140 | 1.210 |
Why?
| | Causality | 4 | 2022 | 105 | 1.200 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 384 | 1.200 |
Why?
| | Proportional Hazards Models | 10 | 2022 | 1076 | 1.190 |
Why?
| | Software | 13 | 2022 | 525 | 1.160 |
Why?
| | Biostatistics | 3 | 2014 | 15 | 1.110 |
Why?
| | Humans | 164 | 2024 | 113531 | 1.080 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 155 | 0.970 |
Why?
| | Microscopy | 3 | 2023 | 125 | 0.930 |
Why?
| | Magnetoencephalography | 2 | 2021 | 99 | 0.920 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 210 | 0.910 |
Why?
| | Lung Neoplasms | 6 | 2022 | 2148 | 0.880 |
Why?
| | Survival Analysis | 11 | 2017 | 1203 | 0.870 |
Why?
| | Histological Techniques | 1 | 2023 | 40 | 0.860 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 285 | 0.840 |
Why?
| | Genetic Association Studies | 5 | 2019 | 333 | 0.830 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1421 | 0.830 |
Why?
| | Connectome | 2 | 2021 | 63 | 0.780 |
Why?
| | Mass Spectrometry | 6 | 2022 | 616 | 0.760 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 28 | 0.750 |
Why?
| | Propensity Score | 4 | 2018 | 225 | 0.730 |
Why?
| | Phenotype | 11 | 2023 | 2754 | 0.720 |
Why?
| | Brain Mapping | 2 | 2021 | 521 | 0.710 |
Why?
| | Endpoint Determination | 2 | 2011 | 68 | 0.710 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 922 | 0.700 |
Why?
| | Risk Assessment | 8 | 2020 | 2953 | 0.680 |
Why?
| | Models, Genetic | 10 | 2019 | 542 | 0.680 |
Why?
| | Image Processing, Computer-Assisted | 7 | 2024 | 681 | 0.680 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 278 | 0.670 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 123 | 0.670 |
Why?
| | Learning | 1 | 2023 | 344 | 0.670 |
Why?
| | Genetic Variation | 4 | 2019 | 854 | 0.650 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 98 | 0.650 |
Why?
| | Glioma | 1 | 2022 | 284 | 0.640 |
Why?
| | Transcriptome | 2 | 2023 | 719 | 0.630 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 153 | 0.630 |
Why?
| | Databases, Factual | 11 | 2020 | 1127 | 0.630 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 115 | 0.630 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 1725 | 0.620 |
Why?
| | Metabolome | 1 | 2021 | 275 | 0.620 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1205 | 0.610 |
Why?
| | Databases, Genetic | 10 | 2021 | 205 | 0.610 |
Why?
| | Logistic Models | 12 | 2020 | 1832 | 0.600 |
Why?
| | Reproducibility of Results | 16 | 2021 | 2752 | 0.580 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 71 | 0.560 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1604 | 0.550 |
Why?
| | Retinol-Binding Proteins | 2 | 2014 | 13 | 0.530 |
Why?
| | Eye Proteins | 3 | 2014 | 69 | 0.530 |
Why?
| | Markov Chains | 7 | 2017 | 114 | 0.510 |
Why?
| | Linear Models | 7 | 2018 | 767 | 0.500 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 322 | 0.490 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.470 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 64 | 0.470 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 575 | 0.470 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 953 | 0.450 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 84 | 0.450 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1157 | 0.450 |
Why?
| | Bayes Theorem | 6 | 2012 | 325 | 0.440 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 143 | 0.430 |
Why?
| | Disease Progression | 14 | 2021 | 2364 | 0.430 |
Why?
| | Bias | 5 | 2022 | 178 | 0.420 |
Why?
| | Treatment Outcome | 7 | 2021 | 9006 | 0.420 |
Why?
| | Cluster Analysis | 9 | 2023 | 448 | 0.410 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 47 | 0.400 |
Why?
| | Oncogenes | 1 | 2013 | 104 | 0.400 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2088 | 0.400 |
Why?
| | Aromatase | 1 | 2012 | 30 | 0.390 |
Why?
| | Male | 59 | 2021 | 55112 | 0.390 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 176 | 0.390 |
Why?
| | Genome | 5 | 2017 | 260 | 0.380 |
Why?
| | Alzheimer Disease | 3 | 2015 | 444 | 0.380 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 108 | 0.380 |
Why?
| | Adenocarcinoma | 4 | 2017 | 787 | 0.370 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 540 | 0.370 |
Why?
| | Liver Neoplasms | 1 | 2015 | 504 | 0.360 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 1856 | 0.360 |
Why?
| | Brain | 3 | 2019 | 2309 | 0.350 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 11 | 0.350 |
Why?
| | Antioxidants | 1 | 2014 | 527 | 0.340 |
Why?
| | Gene Expression | 3 | 2014 | 1397 | 0.340 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 233 | 0.340 |
Why?
| | Proteomics | 5 | 2009 | 808 | 0.330 |
Why?
| | Stem Cells | 3 | 2020 | 538 | 0.330 |
Why?
| | Nerve Tissue Proteins | 3 | 2020 | 521 | 0.330 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 428 | 0.330 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 101 | 0.320 |
Why?
| | Gene Dosage | 1 | 2010 | 129 | 0.320 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 27 | 0.320 |
Why?
| | Signal Transduction | 9 | 2023 | 4439 | 0.320 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 126 | 0.310 |
Why?
| | Sensitivity and Specificity | 10 | 2015 | 1682 | 0.310 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 234 | 0.310 |
Why?
| | Carcinoma | 2 | 2007 | 198 | 0.310 |
Why?
| | Protein Array Analysis | 8 | 2009 | 55 | 0.300 |
Why?
| | Emigration and Immigration | 1 | 2008 | 45 | 0.300 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1286 | 0.300 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.300 |
Why?
| | Statistical Distributions | 1 | 2008 | 7 | 0.300 |
Why?
| | Research Design | 5 | 2021 | 916 | 0.290 |
Why?
| | Probability | 3 | 2021 | 285 | 0.290 |
Why?
| | Chromosome Mapping | 6 | 2017 | 476 | 0.290 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 281 | 0.290 |
Why?
| | Proteome | 3 | 2007 | 335 | 0.290 |
Why?
| | Flow Cytometry | 2 | 2022 | 1065 | 0.280 |
Why?
| | Aged | 27 | 2022 | 18944 | 0.280 |
Why?
| | Tumor Burden | 1 | 2008 | 257 | 0.280 |
Why?
| | Female | 42 | 2022 | 59115 | 0.270 |
Why?
| | Pancreas | 2 | 2020 | 276 | 0.270 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 196 | 0.270 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 896 | 0.270 |
Why?
| | Nerve Net | 2 | 2019 | 227 | 0.260 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 157 | 0.260 |
Why?
| | Placenta | 1 | 2012 | 627 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3013 | 0.250 |
Why?
| | Middle Aged | 29 | 2022 | 26552 | 0.250 |
Why?
| | Monte Carlo Method | 4 | 2017 | 136 | 0.250 |
Why?
| | Cell Proliferation | 5 | 2021 | 2164 | 0.250 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1159 | 0.250 |
Why?
| | Cell Nucleus | 2 | 2019 | 527 | 0.250 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 460 | 0.240 |
Why?
| | False Positive Reactions | 4 | 2012 | 109 | 0.240 |
Why?
| | Replication Origin | 1 | 2004 | 15 | 0.240 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 848 | 0.230 |
Why?
| | ROC Curve | 5 | 2020 | 442 | 0.230 |
Why?
| | Crystallography, X-Ray | 3 | 2019 | 402 | 0.230 |
Why?
| | Histones | 4 | 2020 | 528 | 0.230 |
Why?
| | Risk Factors | 12 | 2022 | 8606 | 0.230 |
Why?
| | Leukemia | 1 | 2006 | 208 | 0.220 |
Why?
| | Data Curation | 1 | 2024 | 11 | 0.220 |
Why?
| | Carrier Proteins | 2 | 2007 | 685 | 0.220 |
Why?
| | Coculture Techniques | 1 | 2004 | 198 | 0.220 |
Why?
| | Breast Neoplasms | 7 | 2014 | 1842 | 0.220 |
Why?
| | Sample Size | 3 | 2008 | 107 | 0.210 |
Why?
| | Lupus Nephritis | 1 | 2023 | 52 | 0.210 |
Why?
| | Statistics as Topic | 2 | 2005 | 287 | 0.210 |
Why?
| | Staining and Labeling | 1 | 2023 | 133 | 0.210 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 136 | 0.210 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 24 | 0.210 |
Why?
| | Carcinogens | 1 | 2003 | 101 | 0.210 |
Why?
| | Personality | 1 | 2004 | 110 | 0.210 |
Why?
| | Organometallic Compounds | 1 | 2023 | 98 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2269 | 0.200 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 149 | 0.200 |
Why?
| | Emphysema | 1 | 2023 | 105 | 0.200 |
Why?
| | Neuroimaging | 2 | 2015 | 249 | 0.200 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 97 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 423 | 0.200 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1110 | 0.200 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 420 | 0.190 |
Why?
| | Artificial Intelligence | 3 | 2008 | 144 | 0.190 |
Why?
| | Brain Waves | 1 | 2021 | 20 | 0.190 |
Why?
| | Epilepsy | 2 | 2021 | 278 | 0.190 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 29 | 0.190 |
Why?
| | Adult | 19 | 2022 | 30245 | 0.190 |
Why?
| | Autoantibodies | 5 | 2020 | 1349 | 0.190 |
Why?
| | Anxiety Disorders | 1 | 2004 | 304 | 0.190 |
Why?
| | Genotype | 8 | 2019 | 1733 | 0.180 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 221 | 0.180 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 603 | 0.180 |
Why?
| | Receptors, Androgen | 2 | 2021 | 131 | 0.180 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 45 | 0.180 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 90 | 0.180 |
Why?
| | Lymphocytes | 2 | 2023 | 321 | 0.180 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 265 | 0.180 |
Why?
| | Case-Control Studies | 7 | 2020 | 2993 | 0.180 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 67 | 0.170 |
Why?
| | Recurrence | 4 | 2010 | 925 | 0.170 |
Why?
| | Precision Medicine | 1 | 2024 | 335 | 0.170 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 405 | 0.170 |
Why?
| | Prognosis | 11 | 2021 | 3318 | 0.170 |
Why?
| | Mexican Americans | 3 | 2008 | 100 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 167 | 0.170 |
Why?
| | Radiography | 1 | 2022 | 803 | 0.170 |
Why?
| | Herpes Zoster Vaccine | 1 | 2022 | 159 | 0.170 |
Why?
| | Exome | 2 | 2018 | 200 | 0.170 |
Why?
| | Tretinoin | 1 | 2020 | 122 | 0.160 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 721 | 0.160 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2293 | 0.160 |
Why?
| | Environmental Exposure | 2 | 2017 | 370 | 0.160 |
Why?
| | Disease | 1 | 2019 | 85 | 0.160 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 40 | 0.160 |
Why?
| | Bone Regeneration | 1 | 2019 | 21 | 0.160 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 71 | 0.160 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 79 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2020 | 153 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 52 | 0.150 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 92 | 0.150 |
Why?
| | Pituitary Gland | 2 | 2009 | 143 | 0.150 |
Why?
| | Wilms Tumor | 1 | 2019 | 67 | 0.150 |
Why?
| | Genetic Markers | 3 | 2015 | 318 | 0.150 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 30 | 0.150 |
Why?
| | Herpes Zoster | 1 | 2022 | 330 | 0.150 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 89 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 499 | 0.150 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 494 | 0.150 |
Why?
| | Animals | 18 | 2021 | 31162 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 81 | 0.140 |
Why?
| | DNA Methylation | 3 | 2017 | 493 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 20 | 0.140 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 519 | 0.140 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1282 | 0.140 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 20 | 0.140 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1006 | 0.140 |
Why?
| | Parkinson Disease | 1 | 2021 | 345 | 0.140 |
Why?
| | Child Health | 1 | 2019 | 127 | 0.140 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 86 | 0.140 |
Why?
| | Peptides | 3 | 2007 | 844 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 154 | 0.140 |
Why?
| | RNA, Messenger | 6 | 2017 | 2507 | 0.140 |
Why?
| | Models, Neurological | 1 | 2019 | 212 | 0.140 |
Why?
| | Epigenomics | 1 | 2017 | 98 | 0.140 |
Why?
| | Aged, 80 and over | 13 | 2022 | 6296 | 0.140 |
Why?
| | Analysis of Variance | 3 | 2017 | 1208 | 0.140 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 82 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 115 | 0.140 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 225 | 0.140 |
Why?
| | Osteogenesis | 1 | 2019 | 180 | 0.140 |
Why?
| | Transcription Factors | 6 | 2017 | 1497 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 55 | 0.140 |
Why?
| | Up-Regulation | 2 | 2018 | 794 | 0.140 |
Why?
| | Beryllium | 1 | 2018 | 146 | 0.140 |
Why?
| | Principal Component Analysis | 1 | 2017 | 174 | 0.140 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 153 | 0.140 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 134 | 0.140 |
Why?
| | Lymph Nodes | 1 | 2019 | 412 | 0.140 |
Why?
| | Mice | 14 | 2021 | 14679 | 0.140 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 528 | 0.140 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 382 | 0.140 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 40 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 137 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 229 | 0.130 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 1 | 0.130 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 3 | 0.130 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 6 | 0.130 |
Why?
| | Normal Distribution | 2 | 2014 | 19 | 0.130 |
Why?
| | Anus Neoplasms | 1 | 2016 | 23 | 0.130 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 30 | 0.130 |
Why?
| | Air Pollution | 2 | 2017 | 166 | 0.130 |
Why?
| | ErbB Receptors | 2 | 2012 | 553 | 0.130 |
Why?
| | Heart Arrest | 1 | 2020 | 293 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 295 | 0.130 |
Why?
| | DNA, Complementary | 3 | 2005 | 254 | 0.130 |
Why?
| | Protein Binding | 4 | 2019 | 1867 | 0.130 |
Why?
| | Anesthesiologists | 1 | 2016 | 11 | 0.130 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 317 | 0.130 |
Why?
| | Transcriptional Activation | 1 | 2018 | 331 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 809 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 498 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 17 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2020 | 505 | 0.130 |
Why?
| | Health Services Research | 1 | 2019 | 373 | 0.130 |
Why?
| | Berylliosis | 1 | 2018 | 177 | 0.130 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 592 | 0.130 |
Why?
| | HIV Infections | 3 | 2022 | 2440 | 0.130 |
Why?
| | Respiratory Sounds | 2 | 2007 | 109 | 0.130 |
Why?
| | Cough | 2 | 2007 | 108 | 0.130 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 325 | 0.130 |
Why?
| | Anal Canal | 1 | 2016 | 83 | 0.130 |
Why?
| | Blood Glucose | 2 | 2022 | 1823 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 305 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2019 | 208 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2020 | 1681 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 288 | 0.120 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 324 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 326 | 0.120 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 834 | 0.120 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 2690 | 0.120 |
Why?
| | Time Factors | 5 | 2016 | 6032 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2019 | 584 | 0.120 |
Why?
| | Schizophrenia | 1 | 2019 | 409 | 0.120 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2361 | 0.120 |
Why?
| | Executive Function | 1 | 2019 | 378 | 0.120 |
Why?
| | Risk | 1 | 2017 | 807 | 0.120 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.120 |
Why?
| | Survival Rate | 4 | 2019 | 1634 | 0.120 |
Why?
| | Leishmaniasis, Visceral | 1 | 2014 | 5 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 4 | 2019 | 2077 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2019 | 497 | 0.120 |
Why?
| | Ants | 1 | 2014 | 25 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 36 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.110 |
Why?
| | Sulfonic Acids | 1 | 2014 | 12 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 323 | 0.110 |
Why?
| | Cohort Studies | 8 | 2017 | 4880 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 48 | 0.110 |
Why?
| | Benzothiazoles | 1 | 2014 | 31 | 0.110 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 79 | 0.110 |
Why?
| | Chromatography, Gel | 1 | 2014 | 121 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 78 | 0.110 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 212 | 0.110 |
Why?
| | Odds Ratio | 3 | 2020 | 953 | 0.110 |
Why?
| | Brain Diseases | 1 | 2015 | 124 | 0.110 |
Why?
| | Influenza, Human | 1 | 2019 | 543 | 0.110 |
Why?
| | Crystallization | 1 | 2014 | 133 | 0.110 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 106 | 0.110 |
Why?
| | Trans-Activators | 3 | 2020 | 356 | 0.110 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 157 | 0.110 |
Why?
| | Estradiol | 2 | 2014 | 450 | 0.110 |
Why?
| | Electronic Health Records | 1 | 2020 | 801 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 693 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 996 | 0.100 |
Why?
| | Child | 9 | 2023 | 18340 | 0.100 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 260 | 0.100 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 786 | 0.100 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 5 | 0.100 |
Why?
| | Heme | 1 | 2012 | 52 | 0.100 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 69 | 0.100 |
Why?
| | Lung | 2 | 2023 | 3497 | 0.100 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 24 | 0.100 |
Why?
| | RNA, Viral | 1 | 2015 | 562 | 0.100 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 10 | 0.100 |
Why?
| | Retina | 1 | 2014 | 258 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 598 | 0.090 |
Why?
| | Motion | 1 | 2012 | 91 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 15 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 2875 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 884 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 78 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 187 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 14 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 80 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 12 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 913 | 0.090 |
Why?
| | Catalytic Domain | 1 | 2012 | 193 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 981 | 0.090 |
Why?
| | Vaccination | 1 | 2019 | 1198 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 149 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 435 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2012 | 94 | 0.090 |
Why?
| | Catalysis | 1 | 2012 | 288 | 0.090 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 760 | 0.090 |
Why?
| | Chemokines | 1 | 2011 | 214 | 0.090 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 912 | 0.090 |
Why?
| | Prevalence | 2 | 2015 | 2244 | 0.090 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 137 | 0.090 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.090 |
Why?
| | Gene Silencing | 2 | 2007 | 169 | 0.090 |
Why?
| | Activities of Daily Living | 2 | 2003 | 348 | 0.090 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 79 | 0.090 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.090 |
Why?
| | Pregnancy | 4 | 2017 | 5490 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 265 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 828 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 8 | 0.080 |
Why?
| | Decision Trees | 2 | 2020 | 81 | 0.080 |
Why?
| | Protein Conformation | 1 | 2012 | 798 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4384 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 660 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 16 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 114 | 0.080 |
Why?
| | Peptide Library | 2 | 2007 | 81 | 0.080 |
Why?
| | Androgens | 2 | 2009 | 166 | 0.080 |
Why?
| | Genes, Recessive | 1 | 2008 | 74 | 0.080 |
Why?
| | Psoriasis | 1 | 2009 | 80 | 0.080 |
Why?
| | Exercise | 1 | 2018 | 1617 | 0.080 |
Why?
| | Homozygote | 1 | 2008 | 186 | 0.080 |
Why?
| | Acculturation | 1 | 2008 | 51 | 0.080 |
Why?
| | Complex Mixtures | 1 | 2007 | 11 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1176 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 320 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 90 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 890 | 0.070 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 156 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 201 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 39 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 625 | 0.070 |
Why?
| | Young Adult | 6 | 2020 | 10400 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 36 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1080 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 302 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 275 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 24 | 0.070 |
Why?
| | Self Concept | 1 | 2009 | 214 | 0.070 |
Why?
| | Genome, Human | 4 | 2016 | 342 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 30 | 0.070 |
Why?
| | Genes, myc | 1 | 2007 | 44 | 0.070 |
Why?
| | Genome, Bacterial | 2 | 2006 | 106 | 0.070 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.070 |
Why?
| | Nails | 1 | 2007 | 8 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 106 | 0.070 |
Why?
| | Mutation, Missense | 1 | 2008 | 293 | 0.070 |
Why?
| | United States | 7 | 2018 | 12137 | 0.070 |
Why?
| | Arsenic | 1 | 2007 | 37 | 0.070 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 48 | 0.070 |
Why?
| | Haemophilus Infections | 1 | 2006 | 28 | 0.070 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 101 | 0.070 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 67 | 0.070 |
Why?
| | DNA, Bacterial | 2 | 2006 | 308 | 0.070 |
Why?
| | Pharynx | 1 | 2006 | 52 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2288 | 0.070 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 543 | 0.070 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 148 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 300 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 30 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 125 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 686 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 24 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 558 | 0.060 |
Why?
| | Body Mass Index | 2 | 2016 | 1952 | 0.060 |
Why?
| | Estrogens | 1 | 2008 | 311 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 110 | 0.060 |
Why?
| | Environmental Monitoring | 1 | 2007 | 250 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2017 | 617 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 349 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 49 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 100 | 0.060 |
Why?
| | Area Under Curve | 2 | 2020 | 271 | 0.060 |
Why?
| | Repressor Proteins | 1 | 2007 | 358 | 0.060 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 11 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 239 | 0.060 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 14 | 0.060 |
Why?
| | Poisson Distribution | 1 | 2004 | 71 | 0.060 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 51 | 0.060 |
Why?
| | Sputum | 1 | 2006 | 284 | 0.060 |
Why?
| | Macrophages | 1 | 2011 | 1233 | 0.060 |
Why?
| | Otitis Media | 1 | 2006 | 142 | 0.060 |
Why?
| | Pedigree | 2 | 2019 | 460 | 0.060 |
Why?
| | Culture Techniques | 1 | 2004 | 76 | 0.060 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 47 | 0.060 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 777 | 0.060 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 40 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 383 | 0.060 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 12 | 0.060 |
Why?
| | Asthma | 2 | 2007 | 2016 | 0.060 |
Why?
| | Cause of Death | 1 | 2006 | 360 | 0.060 |
Why?
| | Genetics, Population | 1 | 2005 | 179 | 0.060 |
Why?
| | Immunophenotyping | 2 | 2020 | 272 | 0.060 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 1 | 0.060 |
Why?
| | Personality Inventory | 1 | 2004 | 130 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 71 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2009 | 716 | 0.060 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 38 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 56 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 124 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2019 | 435 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 68 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 93 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4061 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 114 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 163 | 0.050 |
Why?
| | Breast | 1 | 2003 | 138 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 127 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1008 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 65 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 623 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 107 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 210 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.050 |
Why?
| | Child, Preschool | 3 | 2022 | 9093 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 87 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 33 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 128 | 0.050 |
Why?
| | Biomedical Research | 1 | 2008 | 581 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 939 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 161 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 24 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 31 | 0.050 |
Why?
| | Adolescent | 5 | 2020 | 17724 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 124 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 1136 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 383 | 0.050 |
Why?
| | Genetic Testing | 1 | 2004 | 381 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2005 | 424 | 0.050 |
Why?
| | Entropy | 1 | 2021 | 35 | 0.050 |
Why?
| | Milk, Human | 1 | 2022 | 127 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2016 | 541 | 0.050 |
Why?
| | Citrullination | 1 | 2020 | 12 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2022 | 412 | 0.040 |
Why?
| | Phosphorylation | 2 | 2018 | 1537 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 914 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 2335 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 487 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 18 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 246 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 52 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 28 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 479 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 49 | 0.040 |
Why?
| | Policy | 1 | 2021 | 137 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 225 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 34 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 332 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 211 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 277 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 115 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 613 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 81 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 476 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 366 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 11 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1153 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 19 | 0.040 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 515 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 335 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 314 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 710 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 86 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 193 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 757 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 228 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 222 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4400 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2020 | 2523 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2022 | 377 | 0.040 |
Why?
| | Protein Domains | 1 | 2019 | 207 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 311 | 0.040 |
Why?
| | Autoantigens | 1 | 2020 | 393 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 204 | 0.040 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 38 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 469 | 0.040 |
Why?
| | Protein Stability | 1 | 2018 | 156 | 0.040 |
Why?
| | Melanoma | 1 | 2003 | 620 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 40 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 59 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 551 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 16 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2020 | 12504 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 179 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 96 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 8 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 13 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 123 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 12 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 414 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 46 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 78 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 989 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 737 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 157 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 332 | 0.030 |
Why?
| | Family | 1 | 2019 | 588 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 150 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2019 | 519 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 37 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 585 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 79 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 229 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 178 | 0.030 |
Why?
| | Rats | 1 | 2003 | 4829 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 184 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 254 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 852 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 984 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 155 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 924 | 0.030 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2007 | 58 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 169 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 64 | 0.030 |
Why?
| | Bangladesh | 1 | 2014 | 31 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1359 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 124 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 18 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 13 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 616 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1356 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 81 | 0.030 |
Why?
| | CpG Islands | 1 | 2014 | 118 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 371 | 0.030 |
Why?
| | North America | 1 | 2014 | 256 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 208 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 262 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 92 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2581 | 0.030 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 53 | 0.030 |
Why?
| | Cytokines | 1 | 2020 | 1795 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 177 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1308 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 531 | 0.030 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 81 | 0.030 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 716 | 0.030 |
Why?
| | Prospective Studies | 3 | 2009 | 6189 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 31 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 134 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 89 | 0.020 |
Why?
| | Hospitalization | 1 | 2020 | 1765 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 978 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 187 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 4617 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1131 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 285 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 239 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2076 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1521 | 0.020 |
Why?
| | Infant | 1 | 2022 | 7922 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1356 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 320 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 25 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 3 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1872 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 30 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 40 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 283 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 46 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 364 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 271 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 113 | 0.020 |
Why?
| | Registries | 1 | 2016 | 1762 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 88 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 28 | 0.020 |
Why?
| | Genes | 1 | 2008 | 220 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 654 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 215 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 298 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 4 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 5 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 130 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 141 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 24 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4593 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 496 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1065 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 46 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 339 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 3 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 227 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 337 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 3 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 176 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 19 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 24 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 15 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 39 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 960 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 38 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 42 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 20 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 27 | 0.020 |
Why?
| | Television | 1 | 2007 | 72 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2007 | 196 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 74 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 78 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 65 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2009 | 438 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 132 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 187 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 73 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 89 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1106 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1214 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 146 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1236 | 0.020 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.020 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 55 | 0.020 |
Why?
| | Databases as Topic | 1 | 2005 | 63 | 0.020 |
Why?
| | Housing | 1 | 2006 | 111 | 0.020 |
Why?
| | Base Composition | 1 | 2005 | 75 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 324 | 0.020 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 54 | 0.020 |
Why?
| | DNA Probes | 1 | 2005 | 59 | 0.020 |
Why?
| | Skin | 1 | 2009 | 650 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 4 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 84 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 37 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 49 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 39 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 367 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 175 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 326 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 134 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 76 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 319 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 227 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 473 | 0.010 |
Why?
| | Internet | 1 | 2007 | 590 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 25 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 15 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 49 | 0.010 |
Why?
| | California | 1 | 2003 | 351 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 783 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 538 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3313 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 175 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2741 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 180 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1443 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 483 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 733 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 595 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2009 | 3470 | 0.010 |
Why?
| | RNA | 1 | 2005 | 801 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1016 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1601 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|